Expect Buzz About Rebyota Fecal Product for C. diff

July 2025

Rebyota will be the first fecal microbiota product marketed in Canada for preventing C. difficile recurrence in adults.

It seems unappealing, but a fecal transplant can help restore a healthy GI flora...or “microbiota.”

Patients have recurrent C. difficile if their symptoms return within 2 to 8 weeks after completing antibiotic treatment...and the risk is increased with certain factors such as recent antibiotic use, age 65 or older, and recent hospital admission.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote